Patents by Inventor Shuqian Xu

Shuqian Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220186218
    Abstract: Provided herein are ribonucleoprotein (RNP) complexes comprising a DNA-targeting endonuclease Cas (CRISPR-associated) protein and a guide RNA (gRNA) that that targets and hybridizes to the ?-Globin gene. In one embodiment, the Cas protein is Cas9 and the gRNA comprises the sequence of SEQ ID NO: 1. In one embodiment, the Cas protein is Cas12a and the gRNA comprises the sequence of SEQ ID NO: 3.
    Type: Application
    Filed: January 24, 2020
    Publication date: June 16, 2022
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, UNIVERSITY OF MASSACHUSETTS
    Inventors: Daniel E. BAUER, Shuqian XU, Scot A. WOLFE, Kevin LUK
  • Publication number: 20110165251
    Abstract: The present invention relates to liquid dosage compositions of stable nanoparticulate active agents. The liquid dosage compositions of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the active agent.
    Type: Application
    Filed: March 9, 2011
    Publication date: July 7, 2011
    Inventors: H. William BOSCH, Matthew R. HILBORN, Douglas C. HOVEY, Laura J. KLINE, Robert W. LEE, John D. PRUITT, Niels P. RYDE, Tuula A. RYDE, Shuqian XU
  • Publication number: 20080299210
    Abstract: Disclosed is a population of nanoparticles, together with methods of making a population of nanoparticles, wherein one or more of the nanoparticles includes: an amorphous drug core having an effective diameter less than or equal to about 2.0 microns, wherein the amorphous drug core is substantially free of dopant, and wherein the amorphous drug core includes a drug with properties that satisfy the following relationships: a glass transition temperature greater than or equal to about 50 Deg. C., a glass forming ability less than or equal to about 0.85; and water solubility at 25 Deg. C. less than or equal to about 1 mg/ml; and at least one stabilizer adsorbed on a surface of the amorphous drug core; and wherein the population of nanoparticles exhibits greater than about six months amorphous stability.
    Type: Application
    Filed: April 13, 2007
    Publication date: December 4, 2008
    Inventors: Min Wei, Shuqian Xu, Andrew C. Lam
  • Publication number: 20080181957
    Abstract: Disclosed is a population of nanoparticles, together with methods of making a population of nanoparticles, wherein one or more of the nanoparticles includes: an amorphous drug core having an effective diameter less than or equal to about 2.0 microns, wherein the amorphous drug core is substantially free of dopant, and wherein the amorphous drug core comprises a drug with properties that satisfy the following relationships: a glass transition temperature greater than or equal to about 30 Deg. C.; and water solubility at 25 Deg. C. less than or equal to about 1 mg/ml; and at least one stabilizer adsorbed on a surface of the amorphous drug core; and wherein the at least one stabilizer is present in an amount effective to provide an amorphous stability of the population of nanoparticles that is approximately equal to or greater than an amorphous stability of an amorphous bulk drug substance comprising the drug, as measured over a period of at least four months.
    Type: Application
    Filed: June 22, 2007
    Publication date: July 31, 2008
    Inventors: Min Wei, Shuqian Xu, Andrew C. Lam
  • Publication number: 20040258757
    Abstract: The present invention relates to liquid dosage compositions of stable nanoparticulate active agents. The liquid dosage compositions of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the active agent.
    Type: Application
    Filed: July 16, 2003
    Publication date: December 23, 2004
    Applicant: Elan Pharma International, Ltd.
    Inventors: H. William Bosch, Matthew R. Hilborn, Douglas C. Hovey, Laura J. Kline, Robert W. Lee, John D. Pruitt, Niels P. Ryde, Tuula A. Ryde, Shuqian Xu
  • Patent number: 6221400
    Abstract: The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increased rate of absorption in vivo, a decreased fed/fasted ratio variability, and a decreased variability in absorption. The present invention is also directed to methods of making the novel formulations. In particular, nanoparticulate formulations of HIV type 1 (HIV-1) and type 2 (HIV-2) protease inhibitors are described.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: April 24, 2001
    Assignee: Elan Pharma International Limited
    Inventors: Gary G. Liversidge, David A. Engers, Mary E. Roberts, Stephen B. Ruddy, Sui-Ming Wong, Shuqian Xu
  • Patent number: 6068858
    Abstract: The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increased rate of absorption in vivo, a decreased fed/fasted ratio variability, and a decreased variability in absorption. The present invention is also directed to methods of making the novel formulations. In particular, nanoparticulate formulations of HIV type 1 (HIV-1) and type 2 (HV-2) protease inhibitors are described.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: May 30, 2000
    Assignee: Elan Pharma International Limited
    Inventors: Gary G. Liversidge, David A. Engers, Mary E. Roberts, Stephen B. Ruddy, Sui-Ming Wong, Shuqian Xu
  • Patent number: 6045829
    Abstract: The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increase rate of absorption in vivo, a decreased fed/fasted ratio variability, and a decreased variability in absorption. The present invention is also directed to methods of making the novel formulations. In particular, nanoparticulate formulations of HIV type 1 (HIV-1) and type 2 (HIV-2) protease inhibitors are described.
    Type: Grant
    Filed: July 9, 1997
    Date of Patent: April 4, 2000
    Assignee: Elan Pharma International Limited
    Inventors: Gary G. Liversidge, David A. Engers, Mary E. Roberts, Stephen B. Ruddy, Sui-Ming Wong, Shuqian Xu
  • Patent number: 5705194
    Abstract: There is disclosed a pharmaceutical composition which gels at physiological temperature. The composition is comprised of a block copolymer containing one or more polyoxyethylene blocks and one or more polyoxy (higher alkylene) blocks wherein at least some of the blocks are linked together by a linking group characterised in that the linking group is an oxymethylene group, and a therapeutic agent. The therapeutic agent is present as (i) nanoparticles of the therapeutic agent having the block copolymer adsorbed on the surface thereof, (ii) a suspension in a solution of the block copolymer, or (iii) as an aqueous solution in a solution of the block copolymer.
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: January 6, 1998
    Assignee: NanoSystems L.L.C.
    Inventors: Sui-Ming Wong, Eugene R. Cooper, Shuqian Xu